We characterized the profile of Crohn’s disease (CD) or ulcerative colitis (UC) biologic-naïve patients (starting a new therapy with vedolizumab or TNFα-antagonists), their baseline disease activity predictors, and their perception of the quality of life (HRQoL).
The VEDOIBD-Study is a real-world study on the effectiveness of vedolizumab vs other biologics as induction and maintenance therapy for CD and UC. A total of 627 CD and 546 UC patients were enrolled from IBD-experienced centers across Germany. In both biologic-naïve vedolizumab (n=397) and anti-TNF (n=359) patients, CD and UC disease severity and HRQoL predictors were analyzed with logistic regression. The results were reported as odds ratio (OR) and 95% confidence interval (CI).
When compared to biologic-naïve anti-TNF patients, a first biological therapy with vedolizumab was considered for older CD patients, with a less complicated though longer disease course, and with a history of comorbidities. No differences in (unmet) needs were observed among patients with UC. The presence of extra-intestinal manifestations in biologic-naïve anti-TNF patients with CD (OR (95% CI): 3.83 (1.69–8.68)) and, in both biologic-naïve groups of patients with UC, stool frequency (2.00 (1.25–3.19); 1.82 (1.10–3.02), respectively) and rectal bleeding (2.24 (1.20–4.18); 1.92 (1.19–3.11), respectively) emerged as the most important predictors of disease severity, which in turn were also significantly associated with a worse HRQoL.
This study highlights the existence of unmet medical needs of patients with CD or UC, for whom a new biological therapy is planned as part of the VEDOIBD-Study, which considerably impacts their HRQoL.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Baumgart DC (2009) The diagnosis and treatment of Crohn’s disease and ulcerative colitis. Dtsch Arztebl Int 106(8):123–133. https://doi.org/10.3238/arztebl.2009.0123
Colombel JF (2013) Measuring disability in IBD: the IBD disability index. Gastroenterol Hepatol (N Y) 9(5):300–302
Peyrin-Biroulet L, Cieza A, Sandborn WJ, Coenen M, Chowers Y, Hibi T, Kostanjsek N, Stucki G, Colombel JF, International Programme to Develop New Indexes for Crohn’s Disease g (2012) Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health. Gut 61(2):241–247. https://doi.org/10.1136/gutjnl-2011-300049
Colombel JF (2014) IBD therapy: new targets and unmet needs. Nestle Nutr Inst Workshop Ser 79:153–160. https://doi.org/10.1159/000360720
Brandes A, Groth A, Gottschalk F, Wilke T, Ratsch BA, Orzechowski HD, Fuchs A, Deiters B, Bokemeyer B (2019) Real-world biologic treatment and associated cost in patients with inflammatory bowel disease. Z Gastroenterol 57(7):843–851. https://doi.org/10.1055/a-0903-2938
Schreiber S, Dignass AU, Hartmann H, Kruis W, Rogler G, Siegmund B, Stallmach A, Witte C, Bokemeyer B (2015) Current position on Vedolizumab for ulcerative colitis and Crohn’s disease. Z Gastroenterol 53(6):591–602. https://doi.org/10.1055/s-0034-1399400
Colombel JF, Sands BE, Rutgeerts P, Sandborn W, Danese S, D’Haens G, Panaccione R, Loftus EV Jr, Sankoh S, Fox I, Parikh A, Milch C, Abhyankar B, Feagan BG (2017) The safety of vedolizumab for ulcerative colitis and Crohn’s disease. Gut 66(5):839–851. https://doi.org/10.1136/gutjnl-2015-311079
Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, Lukas M, Fedorak RN, Lee S, Bressler B, Fox I, Rosario M, Sankoh S, Xu J, Stephens K, Milch C, Parikh A, Group GS (2013) Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 369(8):711–721. https://doi.org/10.1056/NEJMoa1215739
Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, Van Assche G, Axler J, Kim HJ, Danese S, Fox I, Milch C, Sankoh S, Wyant T, Xu J, Parikh A, Group GS (2013) Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 369(8):699–710. https://doi.org/10.1056/NEJMoa1215734
Schreiber S, Dignass A, Peyrin-Biroulet L, Hather G, Demuth D, Mosli M, Curtis R, Khalid JM, Loftus EV Jr (2018) Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease. J Gastroenterol 53(9):1048–1064. https://doi.org/10.1007/s00535-018-1480-0
Avorn J (2007) In defense of pharmacoepidemiology--embracing the yin and yang of drug research. N Engl J Med 357(22):2219–2221. https://doi.org/10.1056/NEJMp0706892
Salleron J, Danese S, D’Agay L, Peyrin-Biroulet L (2016) Effectiveness research in inflammatory bowel disease: a necessity and a methodological challenge. J Crohns Colitis 10(9):1096–1102. https://doi.org/10.1093/ecco-jcc/jjw068
Stange EF, Schreiber S, Folsch UR, von Herbay A, Scholmerich J, Hoffmann J, Zeitz M, Fleig WE, Buhr HJ, Kroesen AJ, Moser G, Matthes H, Adler G, Reinshagen M, Stein J, German Society for D, Metabolic D (2003) Diagnostics and treatment of Crohn’s disease -- results of an evidence-based consensus conference of the German Society for Digestive and Metabolic Diseases. Z Gastroenterol 41(1):19–20. https://doi.org/10.1055/s-2003-36661
Stange EF, Travis SP, Vermeire S, Beglinger C, Kupcinkas L, Geboes K, Barakauskiene A, Villanacci V, Von Herbay A, Warren BF, Gasche C, Tilg H, Schreiber SW, Scholmerich J, Reinisch W, Cs E, Colitis O (2006) European evidence based consensus on the diagnosis and management of Crohn’s disease: definitions and diagnosis. Gut 55(Suppl 1):i1–i15. https://doi.org/10.1136/gut.2005.081950a
Stange EF, Travis SP, Vermeire S, Reinisch W, Geboes K, Barakauskiene A, Feakins R, Flejou JF, Herfarth H, Hommes DW, Kupcinskas L, Lakatos PL, Mantzaris GJ, Schreiber S, Villanacci V, Warren BF, Cs E, Colitis O (2008) European evidence-based consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohns Colitis 2(1):1–23. https://doi.org/10.1016/j.crohns.2007.11.001
Brooks R (1996) EuroQol: the current state of play. Health Policy 37(1):53–72. https://doi.org/10.1016/0168-8510(96)00822-6
Elliott AC, Hynan LS (2011) A SAS((R)) macro implementation of a multiple comparison post hoc test for a Kruskal-Wallis analysis. Comput Methods Prog Biomed 102(1):75–80. https://doi.org/10.1016/j.cmpb.2010.11.002
Sauerbrei W, Royston P, Binder H (2007) Selection of important variables and determination of functional form for continuous predictors in multivariable model building. Stat Med 26(30):5512–5528. https://doi.org/10.1002/sim.3148
Crooks B, Barnes T, Limdi JK (2020) Vedolizumab in the treatment of inflammatory bowel disease: evolving paradigms. Drugs Context 9:1–15. https://doi.org/10.7573/dic.2019-10-2
Adar T, Faleck D, Sasidharan S, Cushing K, Borren NZ, Nalagatla N, Ungaro R, Sy W, Owen SC, Patel A, Cohen BL, Ananthakrishnan AN (2019) Comparative safety and effectiveness of tumor necrosis factor alpha antagonists and vedolizumab in elderly IBD patients: a multicentre study. Aliment Pharmacol Ther 49(7):873–879. https://doi.org/10.1111/apt.15177
Asscher VER, Biemans VBC, Pierik MJ, Dijkstra G, Lowenberg M, van der Marel S, de Boer NKH, Bodelier AGL, Jansen JM, West RL, Haans JJL, van Dop WA, Weersma RK, Hoentjen F, Maljaars PWJ, Dutch Initiative on C, Colitis (2020) Comorbidity, not patient age, is associated with impaired safety outcomes in vedolizumab- and ustekinumab-treated patients with inflammatory bowel disease-a prospective multicentre cohort study. Aliment Pharmacol Ther 52(8):1366–1376. https://doi.org/10.1111/apt.16073
Marin-Jimenez I, Bastida G, Fores A, Garcia-Planella E, Arguelles-Arias F, Sarasa P, Tagarro I, Fernandez-Nistal A, Montoto C, Aguas M, Santos-Fernandez J, Bosca-Watts MM, Ferreiro R, Merino O, Aldeguer X, Cortes X, Sicilia B, Mesonero F, Barreiro-de Acosta M (2020) Impact of comorbidities on anti-TNFalpha response and relapse in patients with inflammatory bowel disease: the VERNE study. BMJ Open Gastroenterol 7(1):e000351. https://doi.org/10.1136/bmjgast-2019-000351
Khan N, Vallarino C, Lissoos T, Darr U, Luo M (2020) Risk of infection and types of infection among elderly patients with inflammatory bowel disease: a retrospective database analysis. Inflamm Bowel Dis 26(3):462–468. https://doi.org/10.1093/ibd/izz065
Sandman L, Hofmann B (2019) Why we don’t need “Unmet Needs”! on the concepts of unmet need and severity in health-care priority setting. Health Care Anal 27(1):26–44. https://doi.org/10.1007/s10728-018-0361-2
Bernklev T, Jahnsen J, Lygren I, Henriksen M, Vatn M, Moum B (2005) Health-related quality of life in patients with inflammatory bowel disease measured with the short form-36: psychometric assessments and a comparison with general population norms. Inflamm Bowel Dis 11(10):909–918. https://doi.org/10.1097/01.mib.0000179467.01748.99
Petrak F, Hardt J, Clement T, Borner N, Egle UT, Hoffmann SO (2001) Impaired health-related quality of life in inflammatory bowel diseases: psychosocial impact and coping styles in a national German sample. Scand J Gastroenterol 36(4):375–382. https://doi.org/10.1080/003655201300051171
Min Ho PY, Hu W, Lee YY, Gao C, Tan YZ, Cheen HH, Wee HL, Lim TG, Ong WC (2019) Health-related quality of life of patients with inflammatory bowel disease in Singapore. Intest Res 17(1):107–118. https://doi.org/10.5217/ir.2018.00099
O’Leary CP, Cavender MA (2020) Emerging opportunities to harness real world data: an introduction to data sources, concepts, and applications. Diabetes Obes Metab 22(Suppl 3):3–12. https://doi.org/10.1111/dom.13948
Rubin DB (2007) The design versus the analysis of observational studies for causal effects: parallels with the design of randomized trials. Stat Med 26(1):20–36. https://doi.org/10.1002/sim.2739
Ali MS, Prieto-Alhambra D, Lopes LC, Ramos D, Bispo N, Ichihara MY, Pescarini JM, Williamson E, Fiaccone RL, Barreto ML, Smeeth L (2019) Propensity score methods in health technology assessment: principles, extended applications, and recent advances. Front Pharmacol 10:973. https://doi.org/10.3389/fphar.2019.00973
Loke YK, Mattishent K (2020) Propensity score methods in real-world epidemiology: a practical guide for first-time users. Diabetes Obes Metab 22(Suppl 3):13–20. https://doi.org/10.1111/dom.13926
The authors thank all the physicians and nursing staff of the Kompetenznetz Darmerkrankungen for the recruitment and care of the VEDOIBD-Study participants. We thank Sina Franzenburg and Maren Moser of the Kompetenznetz Darmerkrankungen in Kiel for the study coordination, and Dr. Michelle Rothaug for proofreading the manuscript.
We thank Takeda Pharma Vertrieb GmbH & Co. KG., Berlin, Germany, for the financial support of the VEDOIBD-Study. We also thank the German Inflammatory Bowel Diseases group (GISG) for its cooperation.
The VEDOIBD-Study was funded by Takeda Pharma Vertrieb GmbH & Co. KG., Berlin, Germany.
Study procedures have been approved by the Ethics Committee of the Faculty of Medicine of Kiel University, Germany, (AZ D461/17) in compliance with the Professional Code of Conduct of the Schleswig-Holstein Chamber of Physicians and have therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.
Consent to participate
Informed consent was obtained from all individual participants included in the study.
Consent for publication
Informed consent for publication was obtained from all individual participants included in the study.
Conflict of interest
RdG and SPD have no relevant financial or non-financial interests to disclose.
WM has received consulting fees from Abbvie, Amgen, Hexal, Janssen, Pfizer, Synformulas, and Takeda, outside the submitted work. Fees for lectures and further education from Abbvie, Alanta health service GmbH, Almirall, Aptalis, biogen, Falk, Gilead, Janssen, Pfizer, Medtronic, MSD, Shire, Takeda, and Vifor, outside the submitted work. Fees for studies from Abbvie, Janssen, MSD, Pfizer, and Takeda, outside the submitted work. Fees for activities in public law bodies as member of the Advisory Commission of the Examination Office for the Saarland, the State Committee of Physicians and Health Insurance Companies and the Extended State Committee, outside the submitted work. Dependent employment in the group of Alanta health group GmbH, Hamburg, outside the submitted work. Shares and other fees from Abbvie and Gilead, outside the submitted work.
MH has received fees for studies from Sandoz, Janssen, and Abbvie, outside the submitted work.
TK has received consulting fees from Takeda, Janssen, Pfizer, Ferring, AbbVie, and MSD, outside the submitted work.
BB has received consulting fees from AbbVie, MSD, Shire, Ferring, Hospira, Takeda, Movetis, Shield Therapeutics, Pfizer, Biogen, Janssen, Hexal, and Celgene, outside the submitted work. Financial support for lectures and teaching from AbbVie, Ferring, MSD, Merckle, Falk, HLR, Shield Therapeutics, Pfizer, Celltrion, Takeda, Janssen, and Mundipharma, outside the submitted work. Grant and financial support for research from AbbVie and Ferring, outside the submitted work.
SS has received personal fees from Abbvie, Arena, BMS, Biogen, Celltrion, Celgene, IMAB, Gilead, MSD, Mylan, Pfizer, Fresenius, Janssen, Takeda, Theravance, provention Bio, from Protagonist, and Falk, outside the submitted work.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Romina di Giuseppe and Sandra Plachta-Danielzik contributed equally as first authors.
Bernd Bokemeyer and Stefan Schreiber contributed equally as last authors.
About this article
Cite this article
di Giuseppe, R., Plachta-Danielzik, S., Mohl, W. et al. Profile of patients with inflammatory bowel disease in conjunction with unmet needs and decision-making for choosing a new biologic therapy: a baseline analysis of the VEDOIBD-Study. Int J Colorectal Dis 36, 2445–2453 (2021). https://doi.org/10.1007/s00384-021-03943-5
- Real-world data